department

Clinical
Regulatory
Medical Affairs
Commercial
R&D / Discovery
Biostatistics / Data
Manufacturing / CMC
Market Access

therapeutic area

Oncology
Immunology
Neuroscience
Cardiovascular
Metabolic
Rare Disease
Infectious Disease

location & type

Remote Only
US Only
California
Massachusetts
Internships
Phase 3 Roles
All Jobs →

when

Latest
Archive

by source

All Sources
Sources Page

by activity

Most Active
Biggest Pipelines
Recently Active

hiring

Companies Hiring Now
Big Pharma Roles
All Companies →

Drugs & Pipeline

intelligence

Drugs
Patent Cliff

research

Publications
Topics

window

Next 90 Days
All (incl. Past)

by type

PDUFAs
Approvals
Earnings
Readouts

Sign In Subscribe

pharmadog

fetch the data · sniff the signal

Discover

Calendar
Drugs
Companies
News

Hubs

Topics
Jobs
Patent cliff
Publications

Tools

Compare
Search
Bookmarks

Trust

About
Sources
Contact

Legal

Privacy
Terms
Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

home
jobs
news
cal
search

Genvoya · pharmadog

pharmadog
drugs
Genvoya

drug

patient view →

(cobicistat + elvitegravir + emtricitabine + tenofovir alafenamide fumarate)

Marketedupdated 2mo ago

by $GILD GILEAD SCIENCES, INC.

Approved

community read0 votes

all catalysts(0)

nothing on the calendar yet

News(0)

no news has mentioned this drug yet

brand

Genvoya

generic

(cobicistat + elvitegravir + emtricitabine + tenofovir alafenamide fumarate)

indication

Human Immunodeficiency Virus (HIV) Infections (AIDS)

phase

marketed

Data sources

ClinicalTrials.gov

last refreshed 1h ago

Found something off?

🐶 something off?

Report a data issue

Tell Bork what looks wrong — wrong sponsor, stale phase, mislinked ticker, anything. We’ll triage and fix.

comments(0)

5-min edit window · permanent after that

sign in to leave a comment · permanent archive after 5 minutes

no comments yet — first sniff?

Patent cliff

source: FDA Orange Book

first barrier falls

Aug 27, 2026

51 days

Earliest of all listed patents + FDA exclusivities. Generic / biosimilar entry typically only becomes possible AFTER both patent and exclusivity barriers expire.

patents (18)

Apr 6, 2033patentUS 10039718*PED
Feb 15, 2033patentUS 8754065*PED
Feb 15, 2033patentUS 9296769*PED
Oct 6, 2032formulationUS 10039718
Aug 15, 2032compositionUS 8754065
Aug 15, 2032compositionUS 9296769
Oct 30, 2030patentUS 8633219*PED4.3y
Apr 30, 2030formulationUS 86332193.8y
Mar 3, 2030patentUS 8148374*PED3.7y
Mar 3, 2030patentUS 9891239*PED3.7y
Sep 3, 2029compositionUS 81483743.2y
Sep 3, 2029formulationUS 98912393.2y
Apr 26, 2027patentUS 7635704*PED293d
Apr 26, 2027patentUS 8981103*PED293d
Feb 27, 2027patentUS 7176220*PED235d
Oct 26, 2026compositionUS 7635704111d
Oct 26, 2026compositionUS 8981103111d
Aug 27, 2026compositionUS 717622051d

Trials studying (cobicistat + elvitegravir + emtricitabine + tenofovir alafenamide fumarate)

phase3Switch From Dual Regimens Based on Dolutegravir Plus a Reverse Transcriptase Inhibitor to E/C/F/TAF in Virologically Suppressed, HIV-1 Infected Patients (Be-OnE)terminatedn=100